Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

A Combination of Ipilimumab and Fotemustine for Treat Unresectable Locally Advanced or Metastatic Melanoma (NIBIT-M1)

This study has been completed.
Bristol-Myers Squibb
Information provided by (Responsible Party):
Italian Network for Tumor Biotherapy Identifier:
First received: July 18, 2012
Last updated: May 12, 2015
Last verified: May 2015